GlassScriptPhysician profile
Sona P Dolsenhe
NPI 1104434901
$5,455.27
in general payments reported to CMS, 2019-2025
33 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $1,165 · 2023: $984 · 2024: $1,370 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,599.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $793.55 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $610.84 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $588.50 | 2021-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $521.22 | 2021-2025 | |
| Lilly USA, LLC | $423.44 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $252.79 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $208.99 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $200.89 | 2023-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $200.24 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $181.58 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $181.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $179.61 | 2021-2025 | |
| Pfizer INC. | $163.91 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $136.91 | 2021-2025 | |
| Ionis Pharmaceuticals, INC. | $83.87 | 2025 | Tryngolza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.45 | 2022-2025 | Jardiance |
| Janssen Scientific Affairs, LLC | $75.94 | 2023-2024 | Xarelto |
| Corcept Therapeutics | $71.85 | 2022 | |
| Dexcom, INC. | $71.01 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $65.13 | 2021-2023 | Steglatro |
| Medtronic, INC. | $63.70 | 2023-2025 | Intellis Adaptivestim, Signia |
| Mannkind Corporation | $59.95 | 2023 | Afrezza |
| Astellas Pharma US INC | $49.62 | 2023-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $26.99 | 2024 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $25.23 | 2024 | Givlaari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.61 | 2024 | Caplyta |
| Esperion Therapeutics, INC. | $20.75 | 2025 | Nexletol |
| Irhythm Technologies, INC. | $17.57 | 2023 | Zio Xt Patch |
| Ascensia Diabetes Care US INC. | $17.16 | 2024 | |
| Philips North America LLC | $16.72 | 2024 | (Ck7) Extended Holter |
| Cequr Corporation | $16.13 | 2025 | Cequr Simplicity |
| Endo Pharmaceuticals INC. | $14.65 | 2021 | |
| Convatec INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sona Dolsenhe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.